Table 3.
Oncological follow-up after PC showing (A) the follow-up time and general oncological outcomes, (B) the incidence and time of local recurrence, (C) the incidence and time of distant metastasis, (D) adjuvant and post PC treatment, and (E) the imaging performed during the follow-up.
| Overall cohort (n = 27) |
|
|---|---|
| (A) | |
| Follow-up times and oncological outcomes | |
| Follow-up time of overall cohort (months) | 36.5 (23.3 – 73.8) |
| Minimum follow-up time of overall cohort (months) | 10.0 |
| Follow-up time of survivors (months) | 51.7 (33.9 – 90.9) |
| Minimum follow-up time of survivors (months) | 20.1 |
| Complete disease-free (%) | 12 (44.4) |
| Disease-free time (months) | 56.2 (36.1 – 90.9) |
| MIBC and metastasis-free (%) | 16 (59.3) |
| MIBC and metastasis-free time (months) | 51.9 (36.1 – 90.9) |
| Progression-free (%) | 16 (59.3) |
| Progression-free time (months) | 36.1 (11.8 – 73.8) |
| Life-time bladder preservation (%) | 22 (81.5) |
| Overall death rate (%) | 15 (55.5) |
| Cancer-specific death rate (%) | 9 (36.0) |
| (B) | |
| Local recurrence (%) | 12 (44.4) |
| First local recurrence (%) | |
| Non-MIBC | 9 (33.3) |
| pTa | 5 (18.5) |
| pT1 | 3 (11.1) |
| pTis | 3 (11.1) |
| G1 | 0 (0.0) |
| G2 | 4 (14.8) |
| G3 | 4 (14.8) |
| GX | 1 (3.7) |
| MIBC | 3 (11.1) |
| Local recurrence-free time (months) | 10.4 (6.9 – 20.9) |
| Time to non-MIBC recurrence | 11.5 (7.5 – 18.7) |
| Time to MIBC recurrence | 15.9 (7.3 – 38.1) |
| Local recurrence-free (%) | 15 (55.5) |
| Only non-MIBC in follow-up (%) | 7 (25.9) |
| Progression from non-MIBC to MIBC in follow-up (%) | 2 (7.4) |
| MIBC in follow-up (%) | 5 (18.5) |
| (C) | |
| Distant metastasis (%) | 10 (37.0) |
| Metastasis-free time (months) | 8.9 (4.8 – 27.7) |
| Metastasis-free in follow-up (%) | 17 (63.0) |
| (D) | |
| Post PC treatment | |
| Adjuvant treatment after PC (%) | |
| BCG intravesical instillation | 2 (7.4) |
| Chemotherapy | 4 (14.8) |
| CMV | 1 (3.7) |
| Gemcitabine/Cisplatin | 2 (7.4) |
| Gemcitabine/Carboplatin | 1 (3.7) |
| Treatment of local recurrence (%) | 12 (44.4) |
| Simple TURBT | 7 (25.9) |
| Salvage cystectomy | 5 (18.5) |
| Time to salvage cystectomy from partial cystectomy (months) | 14.0 (7.5 – 43.2) |
| at first local recurrence | 3 (11.1) |
| organ-confined T stage of cystectomy specimen at first local recurrence | 2 (7.4) |
| non-organ-confined T stage of cystectomy specimen at first local recurrence | 1 (3.7) |
| at second local recurrence | 2 (7.4) |
| non-organ-confined T stage of cystectomy specimen at second local recurrence | 2 (7.4) |
| BCG intravesical instillation | 3 (11.1) |
| Treatment of metastatic disease (%) | 8 (29.6) |
| Palliative chemotherapy | 4 (14.8) |
| Gemcitabine/Cisplatin | 2 (7.4) |
| Gemcitabine mono | 1 (3.7) |
| Unknown | 1 (3.7) |
| Metastasectomy | 3 (11.1) |
| Combined radiochemotherapy | 1 (3.7) |
| Radiation therapy | 2 (7.4) |
| (E) | |
| Imaging rate (%) | |
| Urethrocystoscopy | 27 (100.0) |
| Ureterorenoscopy | 0 (0.0) |
| CT/MRI of abdomen/pelvis | 27 (100.0) |
| CT of thorax | 13 (48.1) |
| X-ray of thorax | 4 (14.8) |
| Excretion urogram | 1 (3.7) |
| Bone szintigraphy | 11 (40.7) |
| Sonography | 27 (100.0) |
Continous data are shown as median with interquartile range (IQR). (MIBC) muscle-invasive bladder cancer, (PC) partial cystectomy, (T) tumour, (CT) computed tomography, (MRI) magnetic resonance imaging (G) grading, (BCG) Bacillus-Calmette-Guérin, (TURBT) transurethral resection of bladder tumour, (CMV) Cisplatin, Methotrexat, Vinblastin.